216 related articles for article (PubMed ID: 33677434)
1. Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study.
Okubo K; Arigami T; Matsushita D; Tanaka T; Tsuruda Y; Noda M; Sasaki K; Mori S; Kurahara H; Ohtsuka T
Oncology; 2021; 99(6):380-388. PubMed ID: 33677434
[TBL] [Abstract][Full Text] [Related]
2. Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2011 Aug; 14(3):274-8. PubMed ID: 21461654
[TBL] [Abstract][Full Text] [Related]
3. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
4. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
5. The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage.
Migita K; Takayama T; Saeki K; Matsumoto S; Wakatsuki K; Enomoto K; Tanaka T; Ito M; Kurumatani N; Nakajima Y
Ann Surg Oncol; 2013 Aug; 20(8):2647-54. PubMed ID: 23463091
[TBL] [Abstract][Full Text] [Related]
6. Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
Watanabe H; Hayashi T; Komori K; Hara K; Maezawa Y; Kano K; Shimoda Y; Fujikawa H; Aoyama T; Yamada T; Yamamoto N; Cho H; Ito H; Shiozawa M; Yukawa N; Morinaga S; Yoshikawa T; Rino Y; Masuda M; Ogata T; Oshima T
Anticancer Res; 2020 Mar; 40(3):1683-1690. PubMed ID: 32132075
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
[TBL] [Abstract][Full Text] [Related]
8. Tumor size ≥50 mm as an Independent Prognostic Factor for Patients with Stage II or III Gastric Cancer After Postoperative S-1 Monotherapy: Analysis of a Multi-institution Dataset.
Tsutsuyama M; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
World J Surg; 2020 Jan; 44(1):194-201. PubMed ID: 31552460
[TBL] [Abstract][Full Text] [Related]
9. Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
Tanaka H; Tamura T; Toyokawa T; Muguruma K; Miki Y; Kubo N; Sakurai K; Hirakawa K; Ohira M
Anticancer Res; 2018 Jun; 38(6):3745-3751. PubMed ID: 29848737
[TBL] [Abstract][Full Text] [Related]
10. S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
Yamamoto M; Sakaguchi Y; Kinjo N; Yamaguchi S; Egashira A; Minami K; Ikeda Y; Morita M; Toh Y; Okamura T
Ann Surg Oncol; 2016 Feb; 23(2):546-51. PubMed ID: 26442923
[TBL] [Abstract][Full Text] [Related]
11. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
12. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
[TBL] [Abstract][Full Text] [Related]
13. Using the preoperative prognostic nutritional index as a predictive factor for non-cancer-related death in post-curative resection gastric cancer patients: a retrospective cohort study.
Takechi H; Fujikuni N; Tanabe K; Hattori M; Amano H; Noriyuki T; Nakahara M
BMC Gastroenterol; 2020 Aug; 20(1):256. PubMed ID: 32758144
[TBL] [Abstract][Full Text] [Related]
14. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
[TBL] [Abstract][Full Text] [Related]
15. Preoperative controlling nutritional status (CONUT) score as a predictor of long-term outcome after curative resection followed by adjuvant chemotherapy in stage II-III gastric Cancer.
Liu X; Zhang D; Lin E; Chen Y; Li W; Chen Y; Sun X; Zhou Z
BMC Cancer; 2018 Jun; 18(1):699. PubMed ID: 29954375
[TBL] [Abstract][Full Text] [Related]
16. The Preoperative Prognostic Nutritional Index Predicts Short-Term and Long-Term Outcomes of Patients with Stage II/III Gastric Cancer: Analysis of a Multi-Institution Dataset.
Sasahara M; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
Dig Surg; 2020; 37(2):135-144. PubMed ID: 30840952
[TBL] [Abstract][Full Text] [Related]
17. Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy.
Takahashi R; Ohashi M; Kano Y; Ida S; Kumagai K; Nunobe S; Chin K; Yamaguchi K; Nagino M; Sano T; Hiki N
Gastric Cancer; 2019 Nov; 22(6):1256-1262. PubMed ID: 30877407
[TBL] [Abstract][Full Text] [Related]
18. Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer.
Miyatani K; Saito H; Shimizu S; Kono Y; Murakami Y; Shishido Y; Matsunaga T; Fukumoto Y; Fujiwara Y
Int J Clin Oncol; 2019 Oct; 24(10):1190-1196. PubMed ID: 31104175
[TBL] [Abstract][Full Text] [Related]
19. Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery.
Okuyama T; Korenaga D; Edagawa A; Itoh S; Oki E; Kawanaka H; Ikeda Y; Kakeji Y; Tateishi M; Tsujitani S; Takenaka K; Maehara Y
Surg Today; 2012 Aug; 42(8):734-40. PubMed ID: 22278622
[TBL] [Abstract][Full Text] [Related]
20. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
